NCT03953092View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

November 13, 2019

Study Completion Date

November 13, 2019

Conditions
Diabete Mellitus
Interventions
DRUG

YG1699

YG1699 at Multiple Doses

DRUG

Placebos

Placebos

Trial Locations (1)

07094

Frontage Labs, Secaucus

All Listed Sponsors
lead

Youngene Therapeutics Inc., Ltd.

INDUSTRY

NCT03953092 - A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699 | Biotech Hunter | Biotech Hunter